|
In Vitro Diagnostics and Theranostics: World Market Analysis 2010-2025Übersetzung: In-vitro-Diagnostik und Theranostik: Welt Marktanalyse 2010-2025
|
|||||||||||
| Preis** (Lieferformat): |
Versandkostenfrei ** WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs. |
|||||||||||
| Zahlen und Fakten zur Studie: |
This report gives you the following benefits in particular: 134 seiten | |||||||||||
| Inhalt der Studie: |
Our new report examines the commercial prospects for in vitro diagnostics (IVD) in the global healthcare market. Those technological solutions are playing an important role in clinical practice and ph.....
Our new report examines the commercial prospects for in vitro diagnostics (IVD) in the global healthcare market. Those technological solutions are playing an important role in clinical practice and pharmaceutical R&D - increasing safety, speeding up clinical development and facilitating regulatory acceptance. Molecular diagnostic technologies are leading healthcare towards the goal of personalised medicine, to the benefit of healthcare stakeholders. Molecular diagnostic tests receive support from pharmaceutical regulators, such as the FDA. We believe that some of the greatest opportunities ever available for diagnostics companies are present, with important sales, licensing and partnership developments to occur from 2010 onwards. Pharmaceutical companies also stand to gain, through the benefits of molecular diagnostics. We predict increasing revenues in the years ahead. Do you want to know where the most-promising opportunities will occur? How will companies adapt to the opportunities and challenges? In Vitro Diagnostics and Theranostics: World Market Analysis 2010-2025 answers those and many other questions, providing the information that you require. Our new report also covers theranostics, a fusion of drug therapy and diagnostics to optimise efficacy and safety, as well as streamline drug development. Combining a drug with a diagnostic test is also known as companion diagnostics, integrated medicine, pharmacodiagnostics and Dx/Rx partnering. This emerging field is generating strong interest from the healthcare industry and regulatory bodies, with the associated market expanding as the importance of theranostics is recognised, especially in cancer treatment. Detailed analysis of the in vitro diagnostics industry and market In Vitro Diagnostics and Theranostics: World Market Analysis 2010-2025 examines that sector through a comprehensive review of information sources. We harness both primary and secondary research. This report provides unique sales forecasts, market share analyses, discussions of emerging technologies and analyses of commercial drivers and restraints, including a SWOT analysis. There are over 110 tables and figures included, as well as four interviews with experts. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work. Report Highlights Companies Listed 23andMe Abbott Laboratories AmeriPath Axis-Shield Beckman Coulter Becton, Dickinson & Company BIOTEC Laboratories bioTheranostics Cellestis Center for Disease Control and Prevention (CDC) Clinical Data Complete Genomics Dade Behring Dianon Systems Duke University Dynacare Laboratories Enterix EntroGen Esoterix European Diagnostic Manufacturers Association (EDMA) European Medicines Evaluation Agency (EMEA) Focus Diagnostics Food and Drug Administration (FDA) Genetics & Public Policy Center HemoCue Hologic Home Access Health Laboratory Corporation of America Litholink Corporation Modern Health Systems Monogram Bioscience Myriad Genetics National Genetics Institute National Health Service (UK NHS) Navigenics OraSure Technologies Oxford Immunotec ParagonDx Pathway Genomics Pfizer Prometheus Qiagen Quest Diagnostics Radient Pharmaceuticals Roche Siemens US LABS Vermillion Diagnostics ViroMed Laboratories Walgreens Warner-Chilcott World Health Organization (WHO) [Studien Infos ausblenden] |
|||||||||||
|
1. Executive Summary 1.1 The Scope of this Report 1.2 Chapter Outlines 1.3 Research and Analysis Methods 2. Introduction to In Vitro Diagnostics 2.1 What are In Vitro Diagnostic Tests? 2.2 Classifying IVD: EDMA Classification 2.2.1 Clinical Chemistry 2.2.2 Immunochemistry 2.2.3 Haematology 2.2.4 Microbiology 2.2.5 Genetic Testing 2.3 Classifying IVD: Disease Areas 2.4 Regulatory Issues 2.4.1 FDA Classifications 2.4.2 Regulation of IVD Tests 2.5 Types of IVD Tests 2.6 Personalised Medicine: Pharmacogenomics, Pharmacogenetics, Theranostics, and Proteomics 2.6.1 Pharmacogenomics 2.6.2 Proteomics 2.7 Sensitivity and Specificity 3. In Vitro Diagnostics Market: Global Outlook 2010-2025 3.1 The Global IVD Market in 2009 3.2 Global IVD Market: Forecast 2010-2025 3.3 Global IVD Market: Forecasts by EDMA Category 2010-2025 3.3.1 Clinical Chemistry: Forecast 2010-2025 3.3.2 Immunochemistry: Forecast 2010-2025 3.3.3 Haematology: Forecast 2010-2025 3.3.4 Microbiology (Culture): Forecast 2010-2025 3.3.5 Immunotechnology for Infectious Diseases: Forecast 2010-2025 3.3.6 Genetic Testing: Forecast 2010-2025 3.4 Point-of-Care Testing: Forecast 2010-2025 3.5 Laboratory Testing: Forecast 2010-2025 4. In Vitro Diagnostics: Leading National Markets 4.1 Leading IVD Markets in 2009 4.2 Forecasts by Country 2010-2025 4.3 US IVD Market: Forecast and Outlook 2010-2025 4.4 Japanese IVD Market: Forecast and Outlook 2010-2025 4.5 Leading European IVD Markets: Forecasts and Outlook 2010-2025 4.6 Chinese IVD Market: Forecast and Outlook 2010-2025 4.7 Indian IVD Market: Forecast and Outlook 2010-2025 4.8 How National Market Shares will Change During the Forecast Period 4.9 Global IVD Market by Region 5. Some Leading Companies in the IVD Sector 5.1 IVD Manufacturers 5.1.1 Roche 5.1.2 Siemens AG 5.1.3 Abbott Laboratories 5.1.4 Beckman Coulter 5.1.5 Becton Dickinson 5.2 Laboratory Services 5.2.1 Quest Diagnostics 5.2.2 Laboratory Corporation of America 5.3 Direct-to-Consumer Genomic Testing Companies 6. Important Therapy Areas for IVD Tests 6.1 Diabetes 6.2 Oncology 6.3 Infectious Disease 6.3.1 Hospital-Acquired Infections 6.3.2 HIV 6.3.3 Tuberculosis 6.3.3.1 Skin Tests 6.3.3.2 Smear Microscopy 6.3.3.3 Microbiological Culture 6.3.3.4 Nucleic Acid-Based Testing 6.3.3.5 Immunoassays 6.3.3.6 Phage Assay 6.3.4 Influenza 6.4 Reproductive Tests 6.5 Drugs of Abuse 6.5.1 Drugs Commonly Tested For 6.5.2 Types of Sample 6.6 Cardiovascular Disease 6.6.1 Cardiac Markers 6.6.2 Cholesterol Screening 7. Personalised Medicine and Theranostics 7.1 What is Personalised Medicine? 7.2 Maximising Benefits to Healthcare Stakeholders 7.3 Minimising Harm 7.4 Increasing Patient Compliance 7.5 Streamlining Clinical Trials 7.6 Reviving Failed or Withdrawn Drugs 7.7 Reducing the Costs of Healthcare 7.8 Shifting From Reaction to Prevention 7.9 What is Required for Personalised Medicine to Become Widespread? 7.9.1 The Cost of Genomic Sequencing Must Fall Further 7.9.2 Large-Scale Studies and Databases 7.9.3 A Healthcare IT Infrastructure that Integrates Clinical Data and Other Research 7.9.4 Medical Education 7.9.5 Guaranteed Reimbursements? 7.10 Theranostics Forecast 8. Commercial Drivers and Restraints in the IVD Sector 2010-2025 8.1 SWOT Analysis of the IVD Market Area 8.2 Factors Driving Growth of the IVD Market 8.3 Factors Restraining Growth of the IVD Market 9. Interviews with Industry Experts 9.1 Interview 1: Director of a Diagnostics Company 9.1.1 Most-Promising Therapeutic Areas for IVD 9.1.2 Unmet Medical Needs in IVD 9.1.3 Greatest Obstacles to Market Growth 9.1.4 Prospects for IVD Market Growth in Developing Countries 9.1.5 Prospects for Theranostics 9.2 Interview 2: CEO of a Diagnostics Company 9.2.1 Most-Promising Therapeutic Areas for IVD 9.2.2 Unmet Medical Needs in IVD 9.2.3 Greatest Obstacles to Market Growth 9.2.4 Prospects for IVD Market Growth in Developing Countries 9.2.5 Prospects for Theranostics 9.3 Interview 3: Director of a Diagnostics Company 9.3.1 Most-Promising Therapeutic Areas for IVD 9.3.2 Unmet Medical Needs in IVD 9.3.3 Greatest Obstacles to Market Growth 9.3.4 Prospects for IVD Market Growth in Developing Countries 9.3.5 Prospects for Theranostics 9.4 Interview 4: Business Development Director of a Diagnostics Company 9.4.1 Most-Promising Therapeutic Areas for IVD 9.4.2 Unmet Medical Needs in IVD 9.4.3 Greatest Obstacles to Market Growth 9.4.4 Prospects for IVD Market Growth in Developing Countries 9.4.5 Prospects for Theranostics 10. Conclusions 10.1 In Vitro Diagnostics are Vital to Clinical Decision Making 10.2 Significant Growth of In Vitro Diagnostics Market from 2010 to 2025 10.3 The Top Five Manufacturers Command the Majority of the IVD Market 10.4 Expansion of the World Market Boosted by Rising Sales in the Developing Healthcare Markets 10.5 IVD Solutions are the Cornerstone of Personalised Medicine 10.6 Expansion into Developing National Markets and Lifestyle Diseases Will Drive Market [Inhaltsverzeichnis ausblenden] |
||||||||||||
|
Table 2.1 Criticisms of the CLIA System Table 3.1 Global IVD Market: Revenues by EDMA Category, 2009 Table 3.2 The Global IVD Market: Revenue Forecast, 2010-2025 Table 3.3 Global IVD Market: Revenue Forecast by Submarket, 2010-2015 Table 3.4 Clinical Chemistry IVD Applications, 2010 Table 3.5 Clinical Chemistry IVD Market: Revenue Forecast, 2010-2025 Table 3.6 Immunochemistry IVD Applications, 2010 Table 3.7 Immunochemistry IVD Market: Revenue Forecast, 2010-2025 Table 3.8 Haematology IVD Applications, 2010 Table 3.9 Haematology IVD Market: Revenue Forecast, 2010-2025 Table 3.10 Microbiological Culture Applications, 2010 Table 3.11 Microbiology Culture IVD Market: Revenue Forecast, 2010-2025 Table 3.12 Infectious Immunology Applications, 2010 Table 3.13 Infectious Immunology Market: Revenue Forecast, 2010-2025 Table 3.14 Genetic Testing Applications, 2010 Table 3.15 Genetic Testing Market: Revenue Forecast, 2010-2025 Table 3.16 POCT and Laboratory Testing Market Shares by Revenue, 2009 Table 3.17 The Point-of-Care IVD Market: Revenue Forecast, 2010-2025 Table 3.18 The Laboratory Testing Market: Revenue Forecast, 2010-2025 Table 3.19 The Laboratory Testing and POCT Markets: Revenue Forecasts, 2010-2025 Table 4.1 Leading IVD Markets by Revenue, 2009 Table 4.2 Nine Leading National IVD Markets: Revenue Forecasts, 2010-2025 Table 4.3 The US IVD Market: Revenue Forecast, 2010-2025 Table 4.4 The US IVD Market: Revenue Forecast, 2010-2025 Table 4.5 Healthcare Budgets and IVD Spending of Top Five European Countries, 2009 Table 4.6 The German IVD Market: Revenue Forecast, 2010-2025 Table 4.7 The French IVD Market: Revenue Forecast, 2010-2025 Table 4.8 The Italian IVD Market: Revenue Forecast, 2010-2025 Table 4.9 The Spanish IVD Market: Revenue Forecast, 2010-2025 Table 4.10 The UK IVD Market: Revenue Forecast, 2010-2025 Table 4.11 The Chinese IVD Market: Revenue Forecast, 2010-2025 Table 4.12 The Indian IVD Market: Revenue Forecast, 2010-2025 Table 4.13 Global IVD Market by Regional Revenue Shares, 2009 Table 5.1 Top Five IVD Manufacturers by Revenue, 2009 Table 5.2 Roche: Diagnostic Business Revenues, 2009 Table 5.3 Roche: Bestselling IVD Products, 2009 Table 5.4 Siemens: Revenues by Business Segment, 2009 Table 5.5 Abbott: Revenues by Business Segment, 2009 Table 5.6 Beckman Coulter: Revenues by Business Segment, 2009 Table 5.7 BD: Revenues by Business Segment, 2009 Table 5.8 Quest: Revenues by Business Segment, 2009 Table 5.9 LabCorp: Revenues by Business Segment, 2009 Table 5.10 Conditions Tested for by 23andMe, 2010 Table 6.1 Key Disease Areas: Revenues from IVDs, 2009 Table 6.2 Diabetes Market by Marker, 2009 Table 6.3 POCT by Application, 2009 Table 6.4 Cancer IVD Revenues, 2009 Table 6.5 Theranostics for Oncology, 2010 Table 6.6 Infectious Disease IVD Market by Technology, 2009 Table 6.7 Infectious Disease IVD Market: Revenues by Disease, 2009 Table 6.8 HIV IVD Market: Revenues by Application, 2009 Table 6.9 TB Diagnostics by Revenue, 2009 Table 6.10 Male and Female Fertility Markers, 2010 Table 6.11 Detection Windows for Various DoA Tests, 2010 Table 6.12 Cardiovascular IVD Market: Revenue by Application, 2009 Table 6.13 Common Cardiac Markers, 2010 Table 6.14 Cardiac Marker IVD Market: Revenues by Test Type, 2009 Table 7.1 Comparison of Traditional and Personalised Medicine, 2010 Table 7.2 Average Response Rates to Treatment for Various Diseases, 2010 Table 7.3 Drugs Metabolised by CYP450: 2C19 and 2D6, 2010 Table 7.4 The Falling Cost of Sequencing Complete Human Genome Table 7.5 Diagnostics and Theranostics: Revenue Forecasts, 2010-2025 Table 7.6 Genetic IVDs: Theranostics and Other Tests Revenue Forecasts, 2010-2025 Table 8.1 SWOT Analysis of IVD Market, 2010-2025 Figure 3.1 Global IVD Market: Revenues by EDMA Category, 2009 Figure 3.2 The Global IVD Market: Revenue Forecast, 2010-2025 Figure 3.3 Global IVD Market: Revenue Forecast by Submarket, 2010-2015 Figure 3.4 Clinical Chemistry IVD Market: Revenue Forecast, 2010-2025 Figure 3.5 Immunochemistry IVD Market: Revenue Forecast, 2010-2025 Figure 3.6 Haematology IVD Market: Revenue Forecast, 2010-2025 Figure 3.7 Microbiology Culture IVD Market: Revenue Forecast, 2010-2025 Figure 3.8 Infectious Immunology Market: Revenue Forecast, 2010-2025 Figure 3.9 Genetic Testing Market: Revenue Forecast, 2010-2025 Figure 3.10 POCT and Laboratory Testing Market Shares, 2009 Figure 3.11 The Point-of-Care IVD Market: Revenue Forecast, 2010-2025 Figure 3.12 The Laboratory Testing Market: Revenue Forecast, 2010-2025 Figure 3.13 The Laboratory Testing and POCT Markets: Revenue Forecasts, 2010-2025 Figure 4.1 Leading National IVD Markets by Share of Worldwide Revenue, 2009 Figure 4.2 Leading National IVD Markets (Upper Tier): Revenue Forecasts, 2010-2025 Figure 4.3 Leading National IVD Markets (Lower Tier): Revenue Forecast, 2010-2025 Figure 4.4 The US IVD Market: Revenue Forecast, 2010-2025 Figure 4.5 The Japanese IVD Market: Revenue Forecast, 2010-2025 Figure 4.6 The German IVD Market: Revenue Forecast, 2010-2025 Figure 4.7 The French IVD Market: Revenue Forecast, 2010-2025 Figure 4.8 The Italian IVD Market: Revenue Forecast, 2010-2025 Figure 4.9 The Spanish IVD Market: Revenue Forecast, 2010-2025 Figure 4.10 The UK IVD Market: Revenue Forecast, 2010-2025 Figure 4.11 The Chinese IVD Market: Revenue Forecast, 2010-2025 Figure 4.12 The Indian IVD Market: Revenue Forecast, 2010-2025 Figure 4.13 Market Shares of Leading National Markets, 2010 Figure 4.14 Market Shares of Leading National Markets, 2015 Figure 4.15 Market Shares of Leading National Markets, 2020 Figure 4.16 Market Shares of Leading National Markets, 2025 Figure 4.17 Global IVD Market by Region, 2009 Figure 5.1 Market Shares of the Top Five IVD Manufacturers, 2009 Figure 5.2 Roche: Diagnostic Business by Revenue, 2009 Figure 5.3 Roche: Bestselling IVD Products, 2009 Figure 5.4 Siemens Healthcare: Revenues by Division, 2009 Figure 5.5 Siemens AG: Revenues by Business Segment, 2009 Figure 5.6 Abbott: Revenues by Business Segment, 2009 Figure 5.7 Beckman Coulter: Revenues by Business Segment, 2009 Figure 5.8 BD: Revenues by Business Segment, 2009 Figure 5.9 Quest: Revenues by Business Segment, 2009 Figure 5.10 LabCorp: Revenues by Business Segment, 2009 Figure 6.1 Key Disease Areas: Revenues from IVD Applications, 2009 Figure 6.2 Diabetes Market by Marker, 2009 Figure 6.3 POCT Market by Application, 2009 Figure 6.4 Cancer IVD Revenues, 2009 Figure 6.5 Infectious Disease IVD Market: Revenues by Technology, 2009 Figure 6.6 Infectious Disease IVD Market: Revenues by Disease, 2009 Figure 6.7 HIV IVD Market: Market Shares by Application, 2009 Figure 6.8 TB Diagnostics by Revenue, 2009 Figure 6.9 Cardiovascular IVD: Market Shares by Application, 2009 Figure 6.10 Cardiac Marker IVDs: Market Shares by Test Type, 2009 Figure 7.1 Average Response Rates to Treatment for Various Diseases, 2010 Figure 7.2 The Falling Cost of Sequencing the Whole Human Genome Figure 7.3 Theranostic IVD Market: Revenue Forecast, 2010-2025 Figure 7.4 Global IVD Market: Theranostic and Diagnostic Market Shares, 2010-2025 Figure 7.5 Genetic IVD Applications: Revenue Forecasts for Theranostics and Other Tests, 2010-2025 [Tabellenverzeichnis ausblenden] |
||||||||||||
| Hinweis: | * Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs | |||||||||||
|
|
||||||||||||
